NovoCure

Treatment of Brain Tumors Using Electric Fields

Health Tech & Life Sciences
Public on NASDAQ on Oct, 2015<br>

Company Overview

Snapshot

Founded in April 1999 by Prof. Yoram Palti, NovoCure is a public oncology company with over 1,000 employees. The company has raised $742 million across five funding rounds. In October 2015, NovoCure went public on NASDAQ.

Business overview

NovoCure is a commercial-stage oncology company focused on developing and commercializing Tumor Treating Fields (TTFields) therapy for solid tumor cancers. This proprietary technology utilizes low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division. The therapy is delivered via noninvasive, insulated transducer arrays worn on the skin, connected to a portable electric field generator. NovoCure operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving patients and healthcare providers in markets including the United States, Japan, and Germany.

Strategic signal

In September 2024, NovoCure announced that CEO Asaf Danziger would retire, with CFO Ashley Cordova named as his successor. This leadership transition signals a strategic shift in executive management, potentially impacting the company's future direction and operational focus as it continues to advance its Tumor Treating Fields therapy.

Company Intelligence Q&A

What is NovoCure's core technology?
NovoCure develops Tumor Treating Fields (TTFields) therapy, which uses low-intensity, intermediate-frequency alternating electric fields to disrupt mitosis and cytokinesis in solid tumor cancers.
When did NovoCure go public?
NovoCure went public on NASDAQ in October 2015.
What was a key financial event for NovoCure in May 2024?
In May 2024, NovoCure secured a new $400 million multi-tranche non-dilutive debt financing from Pharmakon.
What significant leadership change occurred in September 2024?
In September 2024, NovoCure announced the planned retirement of CEO Asaf Danziger, with CFO Ashley Cordova named as his successor.
What regulatory approval did NovoCure receive in Japan in September 2025?
In September 2025, NovoCure's Optune Lua® received approval in Japan for the treatment of unresectable advanced/recurrent Non-Small Cell Lung Cancer (NSCLC).

External links